Preoperative Survival Prediction in Patients With Glioblastoma by Routine Inflammatory Laboratory Parameters.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
02 2020
Historique:
received: 04 01 2020
revised: 15 01 2020
accepted: 16 01 2020
entrez: 5 2 2020
pubmed: 6 2 2020
medline: 20 2 2020
Statut: ppublish

Résumé

Glioblastoma (GBM) is the most common malignant brain tumor in adults and still carries a dismal prognosis. As several studies detected a connection between inflammation and GBM prognosis, we sought to explore possible associations between routinely investigated inflammatory parameters and GBM outcome. Patients treated for GBM at our Institution between 2004 and 2014 were included. White blood cell count (WBC), C-reactive protein (CRP) and the ratio of platelets and WBC (Plt/WBC) were evaluated preoperatively. Medical records were reviewed for clinical parameters (age, sex, preoperative clinical condition, genetic alterations). Study endpoints were overall (OS) and 1- and 2-year survival. In the final cohort consisting of 565 individuals with GBM, univariate analysis showed significant associations for WBC, CRP and Plt/WBC ratio with OS. Kaplan-Meier survival plot confirmed significantly poorer OS in patients with WBC>12/nl and with CRP≥2.9 mg/dl. In multivariate analysis, a WBC of >12/nl was an independent prognostic factor for all three outcome parameters and CRP≥2.9 mg/dl for OS and 1-year survival. Preoperative WBC and CRP values were confirmed as independent predictors of GBM outcome. This emphasizes the need for further evaluation of the role of inflammation in the prognosis of GBM.

Sections du résumé

BACKGROUND
Glioblastoma (GBM) is the most common malignant brain tumor in adults and still carries a dismal prognosis. As several studies detected a connection between inflammation and GBM prognosis, we sought to explore possible associations between routinely investigated inflammatory parameters and GBM outcome.
PATIENTS AND METHODS
Patients treated for GBM at our Institution between 2004 and 2014 were included. White blood cell count (WBC), C-reactive protein (CRP) and the ratio of platelets and WBC (Plt/WBC) were evaluated preoperatively. Medical records were reviewed for clinical parameters (age, sex, preoperative clinical condition, genetic alterations). Study endpoints were overall (OS) and 1- and 2-year survival.
RESULTS
In the final cohort consisting of 565 individuals with GBM, univariate analysis showed significant associations for WBC, CRP and Plt/WBC ratio with OS. Kaplan-Meier survival plot confirmed significantly poorer OS in patients with WBC>12/nl and with CRP≥2.9 mg/dl. In multivariate analysis, a WBC of >12/nl was an independent prognostic factor for all three outcome parameters and CRP≥2.9 mg/dl for OS and 1-year survival.
CONCLUSION
Preoperative WBC and CRP values were confirmed as independent predictors of GBM outcome. This emphasizes the need for further evaluation of the role of inflammation in the prognosis of GBM.

Identifiants

pubmed: 32014969
pii: 40/2/1161
doi: 10.21873/anticanres.14058
doi:

Substances chimiques

Biomarkers 0
Inflammation Mediators 0
C-Reactive Protein 9007-41-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1161-1166

Informations de copyright

Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Daniela Pierscianek (D)

Department of Neurosurgery, University Hospital Essen, Essen, Germany daniela.pierscianek@uk-essen.de.
German Cancer Consortium, Partner Site, University Hospital Essen, Essen, Germany.

Yahya Ahmadipour (Y)

Department of Neurosurgery, University Hospital Essen, Essen, Germany.
German Cancer Consortium, Partner Site, University Hospital Essen, Essen, Germany.

Anna Michel (A)

Department of Neurosurgery, University Hospital Essen, Essen, Germany.
German Cancer Consortium, Partner Site, University Hospital Essen, Essen, Germany.

Mehdi Chihi (M)

Department of Neurosurgery, University Hospital Essen, Essen, Germany.
German Cancer Consortium, Partner Site, University Hospital Essen, Essen, Germany.

Marvin Darkwah Oppong (MD)

Department of Neurosurgery, University Hospital Essen, Essen, Germany.
German Cancer Consortium, Partner Site, University Hospital Essen, Essen, Germany.

Sied Kebir (S)

German Cancer Consortium, Partner Site, University Hospital Essen, Essen, Germany.
Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, Essen, Germany.

Martin Glas (M)

German Cancer Consortium, Partner Site, University Hospital Essen, Essen, Germany.
Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, Essen, Germany.

Martin Stuschke (M)

German Cancer Consortium, Partner Site, University Hospital Essen, Essen, Germany.
Department of Radiotherapy, University Hospital Essen, Essen, Germany.

Ulrich Sure (U)

Department of Neurosurgery, University Hospital Essen, Essen, Germany.
German Cancer Consortium, Partner Site, University Hospital Essen, Essen, Germany.

Ramazan Jabbarli (R)

Department of Neurosurgery, University Hospital Essen, Essen, Germany.
German Cancer Consortium, Partner Site, University Hospital Essen, Essen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH